Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Iain B. McInnes, Philip J. Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, R. Landewé, Philip G. Conaghan, Alice B. Gottlieb, Hanno B. Richards, Luminita Pricop, Gregory Ligozio, Manmath Patekar, Shephard Mpofu - The Lancet 2015 cited by 850